A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Reparixin (Primary)
  • Indications Delayed graft function
  • Focus Pharmacokinetics; Registrational
  • Acronyms REP0211
  • Sponsors Dompe Spa
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 May 2017 This trial has been completed in Sweden (end date: 9 Dec 2016).
    • 30 Mar 2017 This trial has been completed in Italy as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top